Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer

PURPOSE: Vorinostat has been shown to overcome resistance to gefitinib. We performed a phase I/II study combining gefitinib with vorinostat in previously treated non-small cell lung cancer (NSCLC). METHODS: A 3 + 3 dose-escalation design was used to determine maximum tolerated dose (MTD) and recomme...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: Han, Ji-Youn, Lee, Soo Hyun, Lee, Geon Kook, Yun, Tak, Lee, Young Joo, Hwang, Kum Hui, Kim, Jin Young, Kim, Heung Tae
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4341018/
https://ncbi.nlm.nih.gov/pubmed/25552401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2664-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados